Switch theme
Sign up to access all valuation multiples
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
1952
1.3K+
LTM Revenue $365M
LTM EBITDA $34.4M
$585M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PolyPeptide has a last 12-month revenue of $365M and a last 12-month EBITDA of $34.4M.
In the most recent fiscal year, PolyPeptide achieved revenue of $383M and an EBITDA of $32.1M.
PolyPeptide expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PolyPeptide valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.0M | $383M | XXX | XXX | XXX |
| Gross Profit | -$256M | -$352M | XXX | XXX | XXX |
| Gross Margin | -5153% | -92% | XXX | XXX | XXX |
| EBITDA | -$25.0M | $32.1M | XXX | XXX | XXX |
| EBITDA Margin | -504% | 8% | XXX | XXX | XXX |
| Net Profit | $8.8M | -$58.2M | XXX | XXX | XXX |
| Net Margin | 177% | -15% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PolyPeptide's stock price is CHF 15 (or $17).
PolyPeptide has current market cap of CHF 493M (or $557M), and EV of CHF 517M (or $585M).
See PolyPeptide trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $585M | $557M | XXX | XXX | XXX | XXX | $-0.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PolyPeptide has market cap of $557M and EV of $585M.
PolyPeptide's trades at 1.5x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.
Analysts estimate PolyPeptide's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PolyPeptide and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $585M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 18.2x | XXX | XXX | XXX |
| P/E | -25.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 212.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPolyPeptide's NTM/LTM revenue growth is 16%
PolyPeptide's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $40K for the same period.
Over next 12 months, PolyPeptide's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PolyPeptide's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PolyPeptide and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7599% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -228% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $40K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 13% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PolyPeptide acquired XXX companies to date.
Last acquisition by PolyPeptide was XXXXXXXX, XXXXX XXXXX XXXXXX . PolyPeptide acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PolyPeptide founded? | PolyPeptide was founded in 1952. |
| Where is PolyPeptide headquartered? | PolyPeptide is headquartered in Switzerland. |
| How many employees does PolyPeptide have? | As of today, PolyPeptide has 1.3K+ employees. |
| Is PolyPeptide publicy listed? | Yes, PolyPeptide is a public company listed on SWX. |
| What is the stock symbol of PolyPeptide? | PolyPeptide trades under PPGN ticker. |
| When did PolyPeptide go public? | PolyPeptide went public in 2021. |
| Who are competitors of PolyPeptide? | Similar companies to PolyPeptide include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of PolyPeptide? | PolyPeptide's current market cap is $557M |
| What is the current revenue of PolyPeptide? | PolyPeptide's last 12-month revenue is $365M. |
| What is the current EBITDA of PolyPeptide? | PolyPeptide's last 12-month EBITDA is $34.4M. |
| What is the current EV/Revenue multiple of PolyPeptide? | Current revenue multiple of PolyPeptide is 1.5x. |
| What is the current EV/EBITDA multiple of PolyPeptide? | Current EBITDA multiple of PolyPeptide is 16.2x. |
| What is the current revenue growth of PolyPeptide? | PolyPeptide revenue growth between 2023 and 2024 was 7599%. |
| Is PolyPeptide profitable? | Yes, PolyPeptide is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
